EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE

被引：0

作者：

Savona, M. R. ^{[1
]}

Kolibaba, K. ^{[2
]}

Conkling, P. ^{[3
]}

Kingsley, E. C. ^{[4
]}

Becerra, C. ^{[5
]}

Morris, J. C. ^{[6
]}

Rifkin, R. M. ^{[7
]}

Laille, E. ^{[8
]}

Kellerman, A. ^{[9
]}

Ukrainskyj, S. M. ^{[9
]}

Dong, Q. ^{[10
]}

Skikne, B. S. ^{[9
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN USA

[2] Northwest Canc Specialists, Dept Hematol, Vancouver, WA USA

[3] Virginia Oncol Associates, Dept Hematol Oncol, Norfolk, VA USA

[4] Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA

[5] Texas Oncol PA North Sammons Canc Ctr, Translat Oncol, Dallas, TX USA

[6] Univ Cincinnati, Inst Canc, Div Hematol Oncol, Cincinnati, OH USA

[7] Rocky Mt Canc Ctr, Med Oncol & Hematol, Denver, CO USA

[8] Celgene Corp, Translat Dev, Summit, NJ USA

[9] Celgene Corp, Clin Dev, Summit, NJ USA

[10] Celgene Corp, Biostat, Summit, NJ USA

来源：

关键词：

D O I：

10.1016/S0145-2126(15)30061-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S29 / S30

页数：2